Carfilzomib, which is used to treat multiple myeloma, has been found to increase the risk of cardiovascular disease (CVD). In order to assess the connection between carfilzomib and cardiovascular adverse events (CVAE), researchers from the Abramson Cancer Center of the University of Pennsylvania reviewed 24 clinical trials that included 2,594 patients with multiple myeloma. The results, published in JAMA Oncology, showed that 18% of multiple myeloma patients taking carfilzomib experienced serious heart conditions such as hypertension, heart failure, heart attacks or arrhythmia.
Alanna McCatty is founder and CEO of McCatty Scholars, an organization that devises and implements financial literacy programs for students to combat the nationwide issue of the loss of educational opportunity due to the ramifications of burdensome student debt. At MedShadow, she reports on new findings and research on the side effects of prescription drugs. She is a graduate of Pace University.
Did you find this article helpful?